Financial Results | Maxcyte 2025 Full Year Revenue USD 33.03 Million Net Loss USD 44.63 Million

Maxcyte(MXCT) posted the Q4 of its 2025 financial results on 3/25/2026, reporting total revenue of USD 33.03 million for the year, down 14.50% from USD 38.63 million year over year, reporting net loss of USD 44.63 million for the year, expanding 8.71% from USD -41.06 million year over year. The EPS is USD -0.42 for the year, compare with USD -0.39 last period.

[Detailed Data]

Million USD	Q4 2025	Q3 2025	Q2 2025	Q1 2025
Total Revenue	7.30	6.83	8.51	10.39
Cost of Sales	1.61	1.60	1.52	1.50
Gross Profit	5.69	5.23	6.99	8.89
Total Operating Expenses	15.29	17.65	19.35	19.15
Operating Income	-9.60	-12.42	-12.36	-10.26
Net Income	-9.60	-12.42	-12.36	-10.26
Net Income Attributable to Common Shareholders	-9.60	-12.42	-12.36	-10.26
EPS(USD)	-0.0899	-0.12	-0.12	-0.1

[Company Profile]
MaxCyte, Inc., was incorporated on July 31, 1998 under the laws and regulations of the State of Delaware. The company is a leading commercial cell engineering firm providing its proprietary Flow Electroporation technology platform to enable the discovery, development, and commercialization of next-generation cell therapies. Its ExPERT platform supports a range of applications across the cell therapy sector, from research to commercial production.